Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women

Carolina S. Vieira; Rui A. Ferriani; Andréa A. Garcia; Mariana K. O. Gomes; George D. Azevedo; Marcos F. Silva de Sá

doi:10.1160/TH05-03-0682

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(03): 682-683
DOI: 10.1160/TH05-03-0682

Letters to the Editor

Schattauer GmbH

Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women

Authors

Carolina S. Vieira

¹Department of Gynaecology and Obstetrics of the University of São Paulo Ribeirão Preto School of Medicine, Ribeirão Preto, Brazil
Rui A. Ferriani

¹Department of Gynaecology and Obstetrics of the University of São Paulo Ribeirão Preto School of Medicine, Ribeirão Preto, Brazil
Andréa A. Garcia

²Department of Haemostasis of the University of São Paulo Ribeirão Preto School of Medicine Hospital das Clínicas, Ribeirão Preto, Brazil
Mariana K. O. Gomes

¹Department of Gynaecology and Obstetrics of the University of São Paulo Ribeirão Preto School of Medicine, Ribeirão Preto, Brazil
George D. Azevedo

³Federal University of Rio Grande do Norte, Brazil
Marcos F. Silva de Sá

¹Department of Gynaecology and Obstetrics of the University of São Paulo Ribeirão Preto School of Medicine, Ribeirão Preto, Brazil

Abstract

Full Text

References

References
1 World Health Organization.. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.. Lancet 1995; 346: 1575-80.
2 Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.. BMJ 2001; 323: 131-4.
3 Singh K, Viegas OA, Koh SC. et al. Effect of long term use of Norplant® implants on haemostatic function.. Contraception 1992; 45: 203-19.
4 Singh K, Viegas OA, Koh SC. et al. Effect of Norplant ® –2 rods on haemostatic function.. Contraception 1992; 45: 71-81.
5 Saleh AA, Ginsburg KA, Duchon TA. et al. Hormonal contraception and platelet function.. Thromb Res 1995; 78: 363-7.
6 Egberg N, van Beek A, Gunnervik C. et al. Effects on hemostatic system and liver function in relation to Implanonï£¨ and Norplantï£¨. A prospective randomized clinical trial.. Contraception 1998; 58: 93-8.
7 Khetawat G, Faraday N, Nealen ML. et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression.. Blood 2000; 95: 2289-96.
8 Jayachandran M, Miller VM. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins.. Platelets 2003; 14: 75-81.
9 Schindler AE, Campagnoli C, Druckmannc R. et al. Classification and pharmacology of progestins.. Maturitas 2003; 46 (Suppl. 01) S7-S16.
10 Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation.. Am J Physiol 1977; 232: 381-5.
11 Lindqvist PG, Rosing J, Malmquist A. et al. Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system.. J Thromb Haemost 2003; 1: 601-2.
12 Rosing J, Tans G, Nicolaes GA. et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.. Br J Haematol 1997; 97: 233-8.
13 Kemmeren JM, Algra A, Meijers JC. et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial.. Blood 2004; 103: 927-33.